Plus Therapeutics

Historical price data

Plus Therapeutics is focused on developing targeted radiotherapeutics for rare and difficult-to-treat cancers, with a mission to deliver high-dose radiation precisely to tumors. The company's core innovation is a proprietary platform combining Rhenium isotopes, nanoliposomes, and biodegradable microspheres to enable localized, image-guided therapy. Key achievements include promising Phase 1 data for its lead candidate, REYOBIQ™, in recurrent glioblastoma and leptomeningeal metastases, and the advancement of a next-generation liver cancer program. Its strategy centers on advancing its clinical pipeline in high-unmet-need oncology indications while leveraging theranostic capabilities.

Proprietary platform combining Rhenium-186/188 isotopes, BMEDA chelation, nanoliposome encapsulation, and biodegradable alginate microspheres (BAM) for targeted, image-guided radiotherapeutics.

Competes in niche CNS markets with few direct radiotherapeutic competitors but faces broader competition from immunotherapies. In liver cancer, must differentiate from established radioembolization products (TheraSphere, SIR-Spheres) with its biodegradable, theranostic microsphere approach.